The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

Verdence Capital Advisors LLC grew its holdings in Boston Scientific Co. (NYSE:BSX – Free Report) by 4.3% in the 3rd quarter, ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Inceptiv is a small device, implanted in the lower torso with leads to the spinal cord, that provides responsive counter-stimulation to relieve chronic pain. The device was approved by the FDA in ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...